Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

Paclitaxel 491Carboplatin 436Gemcitabine 394Docetaxel 386Cisplatin 361pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 222Dexamethasone 213Fluorouracil 212Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 161Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 140Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × EBI-005 × Clear all
NCT04121442 2024-08-06

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Buzzard Pharmaceuticals

Phase 1/2 Completed
15 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡